Synermore Information

Synermore Biologics (Suzhou) Co. Ltd. ("Synermore") is located in beautiful BioBay of Suzhou Industrial Park, and committed to developing and commercializing innovative and biosimilar monoclonal antibodies in the fields of oncology, infectious diseases, and immune disorders. Eric I Tsao, the founder and Chief Executive Officer of Synermore, has over 25 years of experience in biopharmaceutical R & D and manufacturing. Synermore strictly implements the European and American cGMP standards, and file IND or NDA in both China and international. In June 2018, Syneromre was awarded as a Unicorn Breeding Enterprise by Suzhou Industrial Park. So far, 3 varieties have obtained Chinese Clinical Trial Permission and 4 varieties are being carried out Phase I and II clinical trials in the United States and Australia. SYN023 is expected to become the first recombinant humanized rabies mixed monoclonal antibody to be approved and marketed in the world, filling the gap in the global treatment market.